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Abstract
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among premenopausal women,
who often develop insulin resistance. We tested the hypothesis that insulin resistance in skeletal muscle of patients with
polycystic ovary syndrome (PCOS) is an intrinsic defect, by investigating the metabolic characteristics and gene expression
of in vitro differentiated myotubes established from well characterized PCOS subjects.
Methods: Using radiotracer techniques, RT-PCR and enzyme kinetic analysis we examined myotubes established from PCOS
subjects with or without pioglitazone treatment, versus healthy control subjects who had been extensively metabolically
characterized in vivo. Results Myotubes established from PCOS and matched control subjects comprehensively expressed all
insulin-sensitive biomarkers; glucose uptake and oxidation, glycogen synthesis and lipid uptake. There were no significant
differences between groups either at baseline or during acute insulin stimulation, although in vivo skeletal muscle was
insulin resistant. In particular, we found no evidence for defects in insulin-stimulated glycogen synthase activity between
groups. Myotubes established from PCOS patients with or without pioglitazone treatment also showed no significant
differences between groups, neither at baseline nor during acute insulin stimulation, although in vivo pioglitazone
treatment significantly improved insulin sensitivity. Consistently, the myotube cultures failed to show differences in mRNA
levels of genes previously demonstrated to differ in PCOS patients with or without pioglitazone treatment (PLEK, SLC22A16,
and TTBK).
Conclusion: These results suggest that the mechanisms governing insulin resistance in skeletal muscle of PCOS patients in
vivo are not primary, but rather adaptive.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder among premenopausal women affecting 5–8%
of women of reproductive age [1–2]. PCOS is characterized by
hyperandrogenism, chronic anovulation and/or polycystic ovaries
[3–4]. More than 50% of PCOS patients are insulin resistant and
have a diabetes risk 5–8 times higher than age- and weight-matched
controls[5].Theexactmechanism forinsulinresistanceinPCOS is,
however, still unknown [6]. Skeletal muscle is the major site of
insulin mediated glucose disposal (Rd) and muscular insulin
resistance is a major risk factor for type 2 diabetes (T2D) [7] in
PCOS [8]. It is debated whether insulin resistance in PCOS is
similar to insulin resistance in T2D, or if it represents an exclusive
subphenotype [9–11]. The insulin receptor affinity and number in
PCOS patients is equivalent to that of controls, insulin resistance is
presumably mediated through downstream changes in the insulin
receptor-mediated signal transduction cascade [12]. Metabolic
studies of PCOS patients have shown that impaired insulin-
stimulated glucose metabolism is largely accounted for by reduced
non-oxidative glucose metabolism (NOGD) [9]. In agreement with
these results, impaired insulin-stimulated glycogen synthesis has
been documented in vivo in skeletal muscle from women with PCOS
[13]. Furthermore, impaired insulin signaling through AKT and
AS160 changes associated with hyperandrogenemia has been
documented in skeletal muscle cells from women with PCOS [10].
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clarified, and the pathophysiological complexity of the syndrome
complicates genetic analyses [14]. Kashar-Miller et al. found a
PCOS prevalence of 35% and 40% in premenopausal mothers
and sisters of PCOS patients [15]. PCOS is considered an
oligogenetic syndrome and several candidate genes involved in
insulin action, glucose and lipid metabolism have been proposed.
[16–17]. Alterations at the translational level have also been
demonstrated, including down regulation of genes involved in
mitochondrial oxidative phosphorylation, associated with im-
paired insulin-stimulated total, oxidative and nonoxidative glucose
disposal in PCOS patients [18]. A recent microarray study by
Skov et al. [19] demonstrated significant differential expression of
several genes in the skeletal muscle of women with PCOS after
treatment with pioglitazone.
Cultured human myotubes display the morphological, meta-
bolic and biochemical properties of adult skeletal muscle and offer
a unique model to distinguish between genetic and environmental
factors in the etiology of insulin resistance and T2D [20,21]. We
and other have reported a number of potential intrinsic defects in
myotubes established from patients with T2D including impaired
insulin-stimulated glycogen synthesis [20]; reduced glycogen
synthase activity [20–22]; reduced basal glucose uptake [20];
impaired glucose oxidation [23], a reduced TCA flux [24–25] and
a lower basal palmitate oxidation [26] [27–28].
Previous in vitro studies on whether inborn defects, as seen in
myotubes established from T2D subjects, exist in myotubes
established from subjects with PCOS found both increased and
reduced glucose uptake but without insulin resistance [29–30].
To identify primary changes causing impaired insulin respon-
siveness in PCOS myotubes, we compared the metabolic
characteristics of in vitro cultured myotubes from PCOS patients
and healthy matched controls under normal glycemic and normal
insulinemic conditions and after acute insulin stimulation.
Extending previous studies, we aimed to investigate if the
metabolic improvements detected in vivo after 16 weeks pioglita-
zone treatment were also detectable ex vivo in subcultured
myotubes in order to clarify whether in vivo induced changes by
pioglitazone were intrinsically retained in subcultured myotubes.
Results
Glucose and lipid metabolism
As reported previously [9], PCOS subjects had increased fasting
levels of serum insulin, free testosterone, and plasma triglycerides
compared to controls (Table 1). Insulin-stimulated glucose disposal
(Rd) was 50% lower in PCOS subjects than controls (P,0.001),
and this was primarily accounted for by a 60% reduction in
NOGM, but also a 39% decrease in glucose oxidation. Treatment
of PCOS subjects with pioglitazone significantly reduced fasting
serum insulin and improved insulin-stimulated Rd, glucose
oxidation, and NOGM. No significant changes were measured
in fasting Rd and basal glucose metabolism (Rd, glucose oxidation
and NOGM) between PCOS subjects and controls or during
pioglitazone treatment (data not shown).
Metabolic pathways in PCOS during in vitro studies
We established subcultures from twenty-eight of thirty PCOS
subjects and fourteen healthy control subjects. Glucose transport,
glucose oxidation, glycogen synthesis, and lipid uptake were
significantly stimulated during acute insulin stimulation in
myotubes established from subjects with PCOS and healthy
controls. There were no significant differences between groups
either at baseline or during acute insulin concentration (1mmol/l)
(Table 2). The best described defect in the pathophysiology of
T2D is reduced insulin stimulated glycogen synthase activity
Table 1. Clinical and metabolic characteristics of PCOS subjects and control subjects.
Clinical and metabolic
characteristics Control subjects PCOS patients
PCOS patients pre-
treatment
PCOS patients
post-treatment
(n=14) (n=28) (n=9) (n=9)
Age (years) 33.8 (62.1) 31.6 (61.2) 29.4 (62.1) 29.4 (62.1)
Weight (kg) 98.2 (63.8) 94.9 (62.1) 95.3 (62.8) 94.4 (63.3)
BMI (kg/m
2) 33.7 (61.7) 33.2 (60.8) 32.6 (60.9) 32.5 (61.5)
Body fat (%) 40.5 (61.6) 40.4 (61.0) 38.8 (61.4) 39.5 (61.5)
Fasting:
Triglycerides (mmol/l) 0.86 (60.11) 1.66 (60.18)* 1.61 (60.27 1.15 (60.18)
Free testosterone (mg/l) 0.025 (60.003) 0.040 (60.005)* 0.057 (60.009) 0.048 (60.007)
Glucose (mmol/l) 5.6 (60.1) 5.9 (60.1) 5.5 (60.2) 5.2 (60.1)
Insulin (pmol/l) 51 (66) 90 (610)** 113 (621) 55 (610){
FFA (mmol/l) 0.47 (60.04) 0.44 (60.03) 0.48 (60.05) 0.53 (60.06)
Clamp:
Rd (mg/min/m
2) 297 (623) 150 (68)* 128 (617) 172 (620){
Glucose oxidation (mg/min/m
2) 141 (617) 84 (64)* 80 (611) 95 (612){
Lipid oxidation (mg/min/m
2) 1( 66) 23 (62)* 24 (65) 19 (65)
NOGD (mg/min/m
2) 157 (622) 66 (66)* 48 (67) 77 (610){
Data represents mean 6 SEM and P,0.05 is considered significant.
*P#0.001 vs. control subjects.
**P#0.01 vs. control subjects.
{P#0.05 vs. pre-treatment.
doi:10.1371/journal.pone.0014469.t001
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T2D [20,22]. Insulin stimulated glycogen synthase activity was
also impaired in skeletal muscle of PCOS subjects (Table 1) [13].
We measured glycogen synthase activity in myotubes established
from PCOS subjects and controls and found no significant
differences at baseline or during acute insulin stimulation (Table 2).
In order to test whether the impairments in vivo is only translated
into myotubes established from subjects with the highest degree of
hyperandrogenism or hyperinsulinemia, the PCOS group was
subdivided into two groups, individuals with the fourteen lowest
(range 0.77–1.89 nmol/l) and fourteen highest (range 1.91–
4.24 nmol/l) total testosterone levels respectively, or fourteen
lowest (range 38.0–73.0 pmol/l) and fourteen highest (range 79.7–
236.3 pmol/l) insulin levels respectively and further tested for
differences in metabolic phenotype. Subdividing the PCOS group
did not reveal significant differences in the metabolic phenotype
between myotubes established from PCOS subjects with hyper-
androgenism or hyperinsulinemia compared to low hormone
concentrations (Data not shown)
Pioglitazone treatment
In the pioglitazone subgroup, we established subcultures from
nine subjects treated with pioglitazone and nine subjects treated
with placebo. Pioglitazone treatment in vivo resulted in increased
oxidative and non-oxidative glucose disposal, as previously
reported [9,33,34]. To test whether treatment with pioglitazone
was remembered in subcultured myotubes from subjects with
PCOS, we compared the metabolic characteristics of myotubes
established from PCOS subjects before and after pioglitazone
treatment and further assessed by quantitative real-time PCR, the
expression of genes which are not directly associated to the lipid
and glucose metabolism; solute carrier family 22 (SLC22A16),
pleckstrin (PLEK) and tau tubulin kinase 2 (TTBK2). A previous
microarray study of in vivo skeletal muscle tissue of the same PCOS
subjects before and after pioglitazone treatment [19] found these
transcripts significantly differentially expressed; pleckstrin (PLEK)
(p=0.005, FC =4.6), solute carrier family 22 (SLC22A16)
(p=0.03, FC =4.2), and tau tubulin kinase (TTBK2)
(p=0.00002, FC =24.0). Glucose transport, glucose oxidation,
glycogen synthesis, and lipid uptake in myotubes isolated from
subjects with PCOS before and after pioglitazone treatment were
significantly stimulated during acute insulin stimulation. There
were no significant differences between myotubes isolated from
subjects with PCOS before and after pioglitazone treatment either
at baseline or during acute insulin concentration (1mmol/l)
(Table 3). Moreover, no significant changes in expression of the
three selected genes were observed (Table 3).
Discussion
Cultured human myotubes represent a well-characterized in vitro
model system of skeletal muscle in which the extracellular
environment can be controlled precisely and kept consistent over
time [35]. In the present study, we used this model to compare the
metabolic characteristics of myotubes established from PCOS
subjects and healthy matched controls under normal glycemic and
normal insulinemic conditions and after acute insulin stimulation.
We aimed to investigate, if the insulin resistance detected in vivo in
myotubes was also detectable in vitro. In contrast to studies of
myotubes established from T2D subjects, we could not find
significant signs of primary insulin resistance related to glucose or
lipid metabolism in myotubes established from PCOS subjects. In
order to further ensure that PCOS subjects did not express major
primary defects in the glucose metabolism important for insulin
resistance, we assessed the glycogen synthase activity in the same
cultures. The most well described defect in the pathophysiology of
T2D is reduced insulin stimulated glycogen synthase activity
[31,32] and this was demonstrable in myotubes established from
subjects with T2D [20,22]. Glycogen synthase activity in skeletal
muscle tissue of the above PCOS subjects was previously shown to
be significantly impaired, but the insulin stimulation of glycogen
synthase activity in corresponding established myotubes was not
reduced (Table 2). Thus, these data indicate that there are no
intrinsic (inborn) defects in insulin mediated glucose and lipid
metabolism in skeletal muscle of PCOS subjects, and therefore
provide good evidence for the assumption that the impaired
metabolic characteristics reported in vivo are, in large part,
acquired defects caused by in vivo environmental factors. Few
previous studies were performed ex vivo in adipocytes and
myotubes from PCOS patients. Corbould et al found no
impairments of neither basal, nor insulin stimulated glycogen
Table 2. Metabolic characteristics and gene expression of
relevant genes of isolated and cultures skeletal muscle cells
from untreated women with PCOS and controls.
Metabolic characteristics PCOS subjects
Control
subjects
(n=28) (n=14)
Glucose transport (nmol/min/mg)
Baseline 1.99 (60.15) 1.80 (60.16)
Acute insulin stimulation 2.24 (60.17)* 2.16 (60.21)*
Insulin effect (ratio) 1.16 (60.04) 1.20 (60.05)
Glycogen synthesis (nmol/min/mg)
Baseline 0.41 (60.03) 0.47 (60.04)
Acute insulin stimulation 0.63 (60.04)* 0.76 (60.07)**
Insulin effect (ratio) 1.59 (60.05) 1.67 (60.11)
Glucose oxidation (nmol/min/mg)
Baseline 0.15 (60.01) 0.15 (60.01)
Acute insulin stimulation 0.20 (60.02)* 0.18 (60.02)*
Insulin effect (ratio) 1.34 (60.08) 1.20 (60.06)
Lipid uptake (nmol/min/mg)
Baseline 0.84 (60.02) 0.88 (60.03)
Acute insulin stimulation 0.96 (60.03)** 1.04 (60.04)**
Insulin effect (ratio) 1.15 (60.01) 1.19 (60.02)
Lipid oxidation (nmol/min/mg)
Baseline 0.02 (60.00) 0.02 (60.00)
Glycogen synthase activity
0.1 mmol/l G6P
Baseline 0.54 (60.07) 0.54 (60.09)
Acute insulin stimulation 0.75 (60.09)* 0.73 (60.10)*
10 mmol/l G6P
Baseline 9.99 (61.06) 9.73 (61.03)
Acute insulin stimulation 10.40 (61.29) 9.86 (61.20)
FV (0.1/10 mmol/l) %
Baseline 5.41 (60.74) 5.33 (60.52)
Acute insulin stimulation 8.29 (60.86)* 7.77 (60.76)*
Data represents mean 6 SEM and P,0.05 is considered significant.
*P,0.05, baseline vs. acute insulin stimulation.
**P,0.001, baseline vs. acute insulin stimulation.
doi:10.1371/journal.pone.0014469.t002
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data were supported by Ciaraldi et al, reporting impaired insulin
sensitivity but normal rates of maximal insulin-stimulated glucose
transport in isolated adipocytes from PCOS patients vs. controls
[30]. Corbould et al found no significant differences in glycogen
synthesis in myotubes from PCOS subjects compared to healthy
weight matched controls [37]. In contrast, Ciaraldi et al reported
that myotubes from PCOS subjects displayed reduced insulin
responsiveness for glucose uptake suggesting that skeletal muscle
and adipose tissue contribute differently to insulin resistance in
PCOS [30]. PCOS is a heterogenic disease and different
characteristics of included PCOS patients may have affected
results. In the present study, fasting insulin concentrations were
90 pmol/l in contrast to 196 pmol/l in the study by Ciaraldi et al
[30] whereas total testosterone levels in both studies were
1.9 nmol/l [9,30]. We tested whether the impairments in vivo is
only translated into myotubes established from subjects with the
highest degree of hyperandrogenism or hyperinsulinemia, and
subdivided the PCOS group into low/high testosterone or low/
high insulin and tested for differences in metabolic phenotype.
Subdividing the PCOS group did not reveal significant differences
in the metabolic phenotype between myotubes established from
PCOS subjects with hyperandrogenism or hyperinsulinemia
compared to low hormone concentrations.
In cultured fibroblasts from PCOS subjects, insulin stimulated
glycogen synthesis was significantly decreased [38]. However,
fibroblasts are not primary insulin targets, and more consistently, a
previous study by Ciaraldi et al also showed no defects in insulin
stimulated glycogen synthesis in fibroblasts [39]. Another hallmark
of T2D, impaired insulin stimulated glucose transport, previously
shown to be conserved in cultured myotubes established from T2D
subjects [40], was comparable between PCOS subjects and control
subjects in our study. In the study by Ciaraldi et al absolute glucose
uptake was decreased both at baseline insulin stimulation and
during acute insulin stimulation in myotubes established from
PCOS subjects compared to control subjects. However, insulin
sensitivity, as assessed by an insulin dose-response curve, revealed
normal insulin responsiveness and further the expression of
GLUT4 was comparable between PCOS subjects and controls
[30]. Corbould et al found an increase in glucose uptake and
GLUT1 abundance, and evidence for intrinsic defects in insulin
signaling in myotubes established from PCOS, but comparable
GLUT4 content. The defects were insufficient to cause insulin
resistance in vitro [37]. Taken together, studies by Corbould et al,
Ciaraldi et al and this study, consistently show no primary
impairments in insulin sensitivity in myotubes established from
patient with PCOS.
The pathogenesis of PCOS may be characterized by a vicious
cycle involving insulin resistance, central obesity and hyperan-
drogenism [6]. Insulin resistance may be the result of changed
body composition [41], and induces hyperinsulinemia, subse-
quently stimulates ovarian and adrenal hormonal production and
inhibits SHBG production leading to increased testosterone
activity [6]. Insulin sensitizers, such as thiazolidinediones, e.g.
pioglitazone, metformin and lifestyle intervention, improve insulin
resistance and thereby insulin stimulation of the adrenals and
ovaries decreases. Thiazolidinediones stimulate the peroxisome
proliferator-activated (PPAR)-c receptors in the cell nucleus and
thereby activate the transcription of genes that affect glucose and
lipid metabolism [42,43]. This leads to decreased peripheral
adipocyte lipolysis, decreased free fatty acid (FFA) levels, and
decreased visceral fat mass [44–46]. Pioglitazone treatment of
PCOS subjects in vivo showed improved insulin sensitivity, glucose
oxidation, NOGD, and lipid oxidation [9]. Studies on muscle
biopsies from treated PCOS subjects confirmed an improved
glycogen synthase activity, improved insulin signaling through
AKT and AS160 [10], and induced changes in the expression of
various transcripts involved in mitochondrial biogenesis, insulin
signal transduction and glucose and lipid metabolism during
pioglitazone treatment [19]. In myotubes established from the
pioglitazone treated subgroup, we found no significant differences
in the metabolic pathways, nor in the expressional levels of
SLC22A16, PLEK and TTBK2, as previously detected in vivo in
PCOS patients [19] (Table 3). Thus, the in vivo induced changes by
pioglitazone were not intrinsically retained in cultured satellite
cells differentiated to myotubes, thereby strengthening our
conclusion that the impaired metabolic characteristics reported
in vivo are principally, acquired defects.
There are several potential reasons for our discrepancies
between insulin resistance detected in skeletal tissue from PCOS
subjects and the lack of a correlating phenotype when analysing
cultured myotubes. Firstly, this might reflect a predominantly
epigenetic mechanism for the insulin resistance in vivo. Epigenetic
changes in gene expression not due to alterations in the DNA
sequence, can still remain mitotically and transgenerationally
hereditary. Epigenetic alterations are known to contribute to
Table 3. Metabolic characteristics of isolated and cultured
skeletal muscle cells from PCOS subjects before and after
pioglitazone treatment.
Metabolic characteristics and
expression of relevant genes
PCOS subjects
pre-treatment
PCOS subjects
post-treatment
n=9 n=9
Glucose transport (nmol/min/mg)
Baseline 1.79 (60.13) 1.79 (60.12)
Acute insulin stimulation 1.94 (60.14)* 2.14 (60.16)*
Insulin effect (ratio) 1.09 (60.04) 1.20 (60.06)
Glycogen synthesis (nmol/min/mg)
Baseline 0.33 (60.03) 0.35 (60.03)
Acute insulin stimulation 0.52 (60.05)* 0.57 (60.05)*
Insulin effect (ratio) 1.58 (60.08) 1.62 (60.11)
Glucose oxidation (nmol/min/mg)
Baseline 0.13 (60.01) 0.14 (60.01)
Acute insulin stimulation 0.18 (60.01)* 0.16 (60.01)*
Insulin effect (ratio) 1.44 (60.12) 1.20 (60.13)
Lipid uptake (nmol/min/mg)
Baseline 0.83 (60.05) 0.82 (60.03)
Acute insulin stimulation 0.97 (60.05)* 0.96 (60.04)*
Insulin effect (ratio) 1.18 (60.02) 1.17 (60.03)
Lipid oxidation (nmol/min/mg)
Low insulin stimulation 0.015 (60.001) 0.014 (60.001)
Gene expression
SLC22a16 1.26E -05
(62.68E -06)
9.01E -06
(63.81E -06)
PLEK 3.91E -05
(69.23E -06)
2.15E -05
(68.20E -06)
TTBK2 8.32E -04
(61.16E -04)
1.30E-03
(66.27E -04)
Subjects received 16 weeks of treatment with 30 mg pioglitazone once daily.
Data represents mean 6 SEM and P,0.05 is considered significant.
*P,0.05, baseline vs. acute insulin stimulation.
doi:10.1371/journal.pone.0014469.t003
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suggested to contribute to PCOS [49,50]. However, a pilot study
on global DNA methylation of peripheral blood DNA failed to
show significant differences between PCOS subjects and healthy
controls [51], which is in agreement with our data suggesting no
major hereditary defect governing the insulin mediated glucose
metabolism.
It is noteworthy, since we have analysed myotube cultures, that
a gene whose expression is down-regulated by methylation in vivo
may become re-expressed, if cells are grown ex vivo. Stem cell
differentiation is often preceded by cell mitosis and the replication
of methylated DNA produces hemimethylated CpG sites which
could cause loss of effective gene silencing at those sites if they are
not remethylated by endogenous methyltransferase [52]. Given
that a principal target molecule of pioglitazone is PPAR-c, it is also
noteworthy that the effect of forced expression of PPAR-c on stem
cell differentiation was context dependent. It sufficed to induce
transdifferentiation of cultured predetermined myoblasts into
adipocytes, but it could not induce adipogenesis of satellite cells
in vivo [53]. Failure to fully reproduce the tissue microenvironment
ex vivo may mean that complementary genetic defects remain
covert, only able to influence the insulin response pathway within
the in vivo context. Systemic hyperandrogenaemia may be
producing a systemic oxidative stress that contributes to insulin
resistance [54] and studies on cultured rat myotubes exposed to
low (within physiological range) and high testosterone concentra-
tions showed that low testosterone exposure increased IRS-1 and
Akt phosphorylation, demonstrating the link between a hyperan-
drogenic and hyperinsulineamic environment [55]. The fact that
PCOS can be linked to genomic variants such as the serum
antioxidant enzyme paraxonase and variant IGF2 genes [56]
emphasizes the likelihood that multifactorial environmental factors
contribute to the final insulin resistance phenotype.
In conclusion, we found no evidence that insulin resistance in
skeletal muscle of PCOS subjects in vivo is of primary origin, but is
likely due to acquired defects. Further studies are needed to
explain the underlying causes of this acquired insulin resistance in
PCOS patients.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement
The study was approved by the local ethics committee (The
Scientific Ethical Committee for Vejle and Funen Counties, now
referred to as The Scientific Ethical Committee of the Region of
Southern Denmark), and by the Danish Medicines Agency and all
subjects gave written informed consent.
Study subjects
The study subjects have previously been described in papers on
insulin signaling, insulin sensitivity and insulin activation of
glycogen synthase [9,10,13,33].
In brief, thirty reproductively aged Caucasian women with
PCOS were included in the study. Criteria for PCOS were
irregular periods with cycle length .35 days in combination with
total and/or free testosterone above reference interval (upper
limits: total testosterone .1.8, free testosterone .0.035 nmol/l)
and/or hirsutism. Included subjects had elevated fasting insulin
levels (.50 pmol/l) and/or were overweight (body mass index
(BMI) $30 kg/m
2). Patients with diabetes (fasting plasma glucose
$7.0 mmol/l), hypertension, elevated liver enzymes, s-prolactin or
s-TSH outside reference interval, renal dysfunction, and conges-
tive heart disease were not included in the study. Subjects
refrained from oral contraceptive use for at least three months
before evaluation, and no patient took medicine known to affect
hormonal or metabolic parameters.
Fourteen healthy Caucasian premenopausal women matched to
PCOS subjects for BMI and age were studied as controls. All
controls had regular menses (period lengths 28–34 days) and did
not suffer from hyperandrogenemia or hirsutism.
After initial examination (see description below), 15 subjects
were randomized to pioglitazone 30 mg/day (Actos, Takeda, Lilly
A/S) or placebo in a double blind fashion. After a treatment
period of 16 weeks, subjects were admitted for repeated
examinations similar to the initial evaluation program.
Two subjects were excluded from the study: One subject in the
placebo group became pregnant and one subject on pioglitazone
treatment experienced side effects (dizziness, ankle edema, and
anxiety) and was excluded after one week of treatment. All
examinations of the study subjects along with the Euglycemic
hyperinsulineamic clamp were carried out at The Department of
Endocrinology, Odense University Hospital, Odense, Denmark.
Examinations
Examinations were performed during the follicular phase in
patients with oligomenorrhea and in healthy controls. Patients
with amenorrhea (period length .3 months) were examined
randomly. The evaluation program of included subjects was
performed as previously described [9].
Clinical examination
Ferriman-Gallwey score, blood pressure, WHR, heart and lung
stethoscopy, height and weight were determined in all subjects.
Waist circumference was determined as the minimum circumfer-
ence between the iliac crest and lower costae, whereas the hip
circumference was determined as the maximum circumference
over the gluteal region [9]. Clinical characteristics of the study
subject are presented in table 1.
Euglycemic hyperinsulineamic clamp
The clamp protocol has previously been described [9]. After
120 minutes basal tracer equilibration period, insulin (Actrapid,
Novo Nordisk, Bagsvaerd, Denmark) was infused at a rate of
40 mU/m
2 min. for 180 min and plasma glucose levels were
clamped at approximately 5 mmol/l using a variable infusion rate
of 20% glucose. 3-
3H glucose was added to the glucose infusate to
maintain constant levels of plasma specific activity during the
clamp period. Indirect calorimetry was performed during the last
40 minutes of the basal and insulin infusion periods using a
ventilated hood system (Deltatrac 2, SensorMedics, Yorba Linda,
CA) and average gas exchanges were used to calculate glucose-
and lipid oxidation rates and total energy expenditure.
Muscle biopsies were obtained from the vastus lateralis muscle
using a modified Bergstro ¨m needle with suction under local
anaesthesia. Muscle samples were immediately blotted free of
blood, fat and connective tissue and frozen in liquid nitrogen
within 30 seconds.
Calculations
Steele’s non-steady state formulas were used to calculate rates of
total glucose appearance (Ra) and Rd assuming a glucose
distribution volume of 200 ml/kg body weight and a pool fraction
of 0.65 [9]. NOGD was calculated as the difference between Rd
Insulin Resistance in PCOS
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infusion rate (GIR) during the last 20 minutes of the insulin
infusion period was used for calculation of whole body insulin
sensitivity (Si). Si was calculated as GIR divided by the
incremental increase in insulin concentration from the basal to
the insulin-stimulated period during the clamp and divided by the
mean glucose concentration during the last 40 minutes of the
insulin clamp.
Assays
Serum total testosterone was analyzed using a specific
radioimmunoassay (RIA) after extraction as previously described
[57]. This method has a close correlation with the determination
of testosterone levels using mass spectrometry. Sex hormone
binding globulin (SHBG) was analyzed by time-resolved immu-
noassay using AutoDELFIA commercial kit (Wallac Oy, Turku,
Finland). The intra-assay CV for total testosterone was 8.2% and
for SHBG it was 5.2%. The inter-assay CV for total testosterone
was 13.8% and for SHBG it was 7.5%. Plasma FFA was analyzed
by enzymatic colonimetric reactions (Modular P, Roche). Serum
levels of insulin, C-peptide and estradiol were analysed by time-
resolved fluoroimmunoassay (AutoDELFIA, Wallac Oy, Turku,
Finland). Bedside plasma glucose during the euglycaemic hyper-
insulinaemic clamps was measured using the glucose oxidase
method (Glucose analyser 2, Beckman Instruments). Tritiated
glucose specific activity was determined on barium/zinc depro-
teinised samples as previously described [58].
Myotube cultures
Dulbecco’s modified Eagle’s medium (DMEM), heat inactivated
fetal calf serum (FCS), penicillin-streptomycin-amphotericin B,
and trypsin-EDTA were obtained from Invitrogen (Invitrogen,
Scotland, UK). Ultroser G was purchased from Pall Biosepra
(Cergy-Saint-Christophe, France). Protein assay kit was purchased
from BioRad (Copenhagen, Denmark). Palmitic acid, L-carnitine,
and ECM-gel were purchased from Sigma Chemical Co. (St.
Louis, USA). Bovine serum albumin (BSA) (essentially fatty acid
free) was from Calbiochem (VWR, Roskilde, Denmark). Insulin
Actrapid was from Novo Nordisk (Bagsvaerd, Denmark).
Cell cultures were established as previously described
[35,59,60]. In brief, muscle tissue was minced, washed and
dissociated for 60 min. by three treatments with 0.05% trypsin-
EDTA. The cells obtained were seeded for up-scaling on ECM-gel
coated dishes after 30 minutes of pre-plating. Growth medium
contained DMEM supplemented with 2% heat inactivated FCS,
2% Ultroser G, 50 U/ml penicillin, 50 mg/ml streptomycin and
1.25 mg/ml amphotericin B. Cells were sub cultured twice before
final seeding. At 75% confluence, the growth medium was
replaced by basal medium (DMEM supplemented with 2% heat
inactivated FCS, 50 U/ml penicillin, 50 mg/ml streptomycin,
1.25 mg/ml amphotericin B, and supplemented with 25 pmol/l
insulin) in order to induce differentiation. The cells were cultured
in humidified 5% CO2 atmosphere at 37uC, and medium was
changed every 2–3 days. Human myotubes established from
women with PCOS, control subjects and PCOS subjects before
and after pioglitazone treatment were allowed to differentiate
under physiological conditions of insulin (25 pmol/l) and glucose
(5.5 mmol/l) for eight days. All myotube cultures were used for
analysis on day eight after onset of differentiation.
Methodological considerations
Optimal culture and differentiation conditions have been
previously established for human myotubes cultures [35,59] and
current cultures were adequately established and differentiated in
accordance with these procedures. To ensure maximal insulin
response in all cultures, we used a maximal insulin concentration
of 1 mmol/l instead of 100 nmol/l, which is used by other groups
[61]. High insulin level may generate a significant signaling
through the IGF-1 receptor which could mask the detection of
insulin resistance. Henry et al compared the dose responds for
insulin and IGF1 on glucose uptake in human myotubes and
found similar sensitivity for insulin and IGF1 [61]. The various
metabolic pathways in human myotube respond by different
magnitudes to insulin stimulation i.e. glycogen synthesis increases
up to two fold, glucose oxidation up to 50%, while glucose uptake
only increases 20–40% [23,62,63]. In the present study we studied
several insulin sensitive pathways in order to reduce the possible
limitation in evaluation of insulin resistance only at one level as the
glucose transport, thereby increasing the chance to detect insulin
resistance, if present.
Substrate oxidation
Glucose and palmitate oxidation was determined by a 96 multi-
well tracer technique as previous described [64]. Substrate
oxidation was monitored by incubating myotubes with [1-
14C]-
Palmitate (2.0 mCi/ml) in a final concentration of 0.4 mmol/l
palmitate and [
14C(U)]-glucose (2.0 mCi/ml) in a final concentra-
tion of 5.0 mmol/l glucose with subsequent capture of liberated
14CO2 for 4 h at 37uC. Trapped radioactivity was determined
with a Microbeta counter (PerkinElmer, Finland).
Glucose and lipid uptake
Glucose uptake was measured by capturing 2-[1-
14C]-deoxy-
glucose and lipid uptake was measured as the incorporation of
[1-
14C]-Palmitate (2.0 mCi/ml) as previously described [40,23].
Radioactivity was determined with a Microbeta counter (Perki-
nElmer, Finland).
Glycogen synthesis
Glycogen synthesis was measured as previous described in 96
well plates [23]. Radioactivity was measured with a Microbeta
counter (PerkinElmer, Finland).
Glycogen synthase activity
The GS activity was measured as described by Mandarino et al.
[65]. Cells were washed three times with ice-cold PBS, and 700 ml
GS buffer (50 mmol/l Hepes, 10 mmol/l EDTA, 100 mmol/l
NaF, 5 mmol/l DTT, 1 mmol/l leupeptin, 1 mmol/l pepstatin and
200 mmol/l phenylmethylsulfonyl flouride, pH 7.5) was added to
each Petri dish. Cells were scraped from the dishes into cryotubes,
sonicated 15 seconds twice at 4uC (Sinirep 150, amplitude 14
microns), frozen and stored at -80uC. Aliquots of sonicate were
used for determination of GS activity and protein. GS activity was
determined at 0.3 mmol/l UDP-glucose, in parallel incubations
with: 0, 0.05, 0.1, 1.0 and 10 mmol/l glucose-6-phosphate. GS
activity was expressed as nanomoles of UDP-glucose incorporated
into glycogen per minute per milligram of total protein. The
specific GS activity was calculated as the above GS activity divided
by the amount of GS protein determined by western blotting and
expressed as nanomoles of UDP-glucose incorporated into
glycogen per minute per OD GS protein. FV0.1 (fractional
velocity) was calculated as the ratio of GS activity determined at
0.1 mmol/l G6P and 10 mmol/l G6P.
RNA isolation and real time PCR
TTBK1 is a serine/threonine/tyrosine kinase that is specifically
expressed in the brain [66]; SLC22A16 is an organic cation
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[67]; PLEK is the major substrate of protein kinase C in platelets
[68].
The expression of SLC22A16, PLEK and TTBK2 was
measured using real time PCR. RNA was prepared from the cells
using the ABI PRISM 6100 Nucleic Acid PrepStation (Applied
Biosystems, Nearum, Denmark) and the Total RNA Isolation
Chemistry Kit (cat. no. 4328773, Applied Biosystems, Nearum,
Denmark). Briefly, the cells were lysed in the dish and transferred
to the RNA purification tray. The lysate was passed through the
tray using vacuum, and the RNA bound to the membrane. The
RNA was eluted, and the concentration and purity was measured
using a NanoDrop spectrophotometer (Thermo Fischer Scientific,
Soeborg, Denmark).
RNA was reverse transcribed using the High Capacity cDNA
Reverse Transcription Kit (cat. no. 4368814, Applied Biosystems,
Nearum, Denmark). Real-time RT-PCR was performed with the
StepOnePlusReal-TimePCRSystemandSYBRGreenPCRMaster
Mix (both from Applied Biosystems, Nearum, Denmark). Each
sample was run in duplicate using 15 ng RNA equivalents per
reaction. The expression value of each gene was normalized against
the amount of b-actin and calculated by the DDCt method [69]. The
following human specific primers were used (DNA Technology A/S,
Denmark): PLEK (forward: GCTGGTATCCAACCAGTCTG,
reverse: CATTGAGCAGCGATGAAGCA); SLC22A16 (forward:
GCCCTCCTGAGTGGAGTGTTAA, reverse: TTTCATTCTC-
TGACTCCAGTTTTGC); TTBK2 (forward: GCTTGGCTCGA-
CAATTTACC, reverse: CTGACCAACCACAAACTCCA). The
quantification of each target gene and b-ACTIN mRNA was
performed in separate tubes. Gene expression levels for each target
gene were calculated using the comparative Ct method [(1/(2DCt)
formula, where DCt is the difference between Ct target and Ct-
reference] after normalization to b-ACTIN mRNA (PerkinElmer’s
User Bulletin No. 2). Data were analyzed using optical system
software version 3.1 (Bio Rad) and Microsoft Excel 2000 to generate
relative expression values [70].
Statistical analysis
Statistical significance was evaluated using Student’s t-test and
calculated two tailed P values. Paired analysis was performed for
comparison of acute and chronic insulin exposure in the same sets
of myotubes.
The data in the text, tables, and figures are given as mean +/2
SEM. The statistical analysis was performed with INSTAT 2.01
(GraphPad, USA). P,0.05 was considered to be significant.
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